SIRO to sponsor expert session on Stratified approaches in Oncology drug development with
Dr. Eric Rowinsky during ASCO 2011
A new paradigm to demonstrate robust clinical benefit, accelerate approvals and conserve costs.
SIRO Clinpharm, a leading clinical research organization (CRO) from Europe and Asia today announced sponsorship of an evening
networking session on Stratified approaches in Oncology drug development. The session will be addressed by the well known
Oncology drug development expert, Dr. Erick K. Rowinsky.
The event is scheduled for the 3rd and 4th of June 2011, at the stunning Everest Restaurant in Chicago. It is being conducted
concurrently with ASCO 2011, to facilitate the attendance of Oncologists and clinical development personnel from Oncology
companies across the United States and Canada.
Stratified drug development is being increasingly looked upon as a new paradigm to demonstrate robust clinical benefit,
accelerate approvals and conserve costs.
The convergence of the biotechnology and the understanding of cancer biology have resulted in diverse cancer therapies that
target aberrations of fundamental proliferative and survival processes in the cancer cell. Many of these new agents have high
therapeutic indices in their targeted cancers and only a small proportion of patients with any given cancer subtype may achieve
robust clinical benefit.
"The Industry is now compelled to pursue specific subtypes of patients due to intense competition for precious patient
resources, increasing cost pressures and the acknowledgement that enrichment strategies will accelerate drug development"
said Dr. Anand Bidarkar, Vice President of SIRO Clinpharm for the Americas. "We are closely engaged with the Oncology drug
development community and sponsoring this session is our way of being useful to them."
The presentation will highlight the problems and issues of utilizing traditional clinical development paradigms and broad
patient populations for developing "rationally designed" and "targeted therapeutics". It will explore the advantages of
developing such therapies in cancer subsets based on a scientific rationale. Further details can be obtained from
About Dr. Erik K. Rowinsky
Dr. Rowinsky served as the Chief medical officer of ImClone Systems and is a member of the boards of directors of Biogen Idec,
Adventrx Pharmaceuticals and Neoprobe. He was on Board of Scientific Counselors of the National Cancer Institute. For further
details visit http://people.forbes.com/profile/eric-k-rowinsky/1753
SIRO Clinpharm is a leading, full service clinical research organization with presence in more than 20 countries in Europe and
Asia. SIRO has supported more than 30 American companies in conducting Oncology studies in Key indications outside of North
This activity is not a part of the ASCO 2011, nor does it purport to do so.